Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial

MLA

Luca Malorni, et al. Serum Thymidine Kinase Activity in Patients with HR-Positive/HER2-Negative Advanced Breast Cancer Treated with Ribociclib plus Letrozole: Results from the Prospective BioItaLEE Trial. Jan. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....55f3932b08062cee1e02a651cffdddd0&authtype=sso&custid=ns315887.

APA

Luca Malorni, Giampaolo Bianchini, Roberta Caputo, Alberto Zambelli, Fabio Puglisi, Giulia V. Bianchi, Lucia Del Mastro, Ida Paris, Filippo Montemurro, Giacomo Allegrini, Marco Colleoni, Stefano Tamberi, Claudio Zamagni, Marina E. Cazzaniga, Michele Orditura, Valentina Guarneri, Daniela Castelletti, Matteo Benelli, Mariacristina Di Marino, … Michelino De Laurentiis. (2023). Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.

Chicago

Luca Malorni, Giampaolo Bianchini, Roberta Caputo, Alberto Zambelli, Fabio Puglisi, Giulia V. Bianchi, Lucia Del Mastro, et al. 2023. “Serum Thymidine Kinase Activity in Patients with HR-Positive/HER2-Negative Advanced Breast Cancer Treated with Ribociclib plus Letrozole: Results from the Prospective BioItaLEE Trial,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....55f3932b08062cee1e02a651cffdddd0&authtype=sso&custid=ns315887.